KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)

Johnson & Johnson recorded quarterly Cash & Current Investments of $22.1 billion in Q1 2026, up 9.7% quarter-over-quarter from $20.1 billion in Q4 2025, and down 43.14% year-over-year from $38.8 billion in Q1 2025.

Johnson & Johnson's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $22.1 billion for Q1 2026.

  • In Q1 2026, Cash & Current Investments fell 43.14% year-over-year to $22.1 billion; the TTM figure through Mar 2026 stood at $22.1 billion (down 43.14% YoY), while the FY2025 annual figure was $20.1 billion, down 18.02% from the prior year.
  • Cash & Current Investments came in at $22.1 billion for Q1 2026 at Johnson & Johnson, up from $20.1 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $38.8 billion in Q1 2025 to a low of $18.6 billion in Q3 2025.
  • A 5-year average of $25.9 billion and a median of $24.6 billion in 2023 frame the typical range for Cash & Current Investments.
  • Across the five-year window, Cash & Current Investments surged 47.92% in 2025 and slumped 43.14% in 2026, its largest moves.
  • Johnson & Johnson's Cash & Current Investments stood at $34.1 billion in 2022, then plunged by 32.72% to $22.9 billion in 2023, then advanced by 6.96% to $24.5 billion in 2024, then retreated by 18.02% to $20.1 billion in 2025, then climbed by 9.7% to $22.1 billion in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $22.1 billion, $20.1 billion, and $18.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 5.28 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 22.05 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 9.39 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 5.70 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 7.64 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 13.08 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 10.49 Bn
10 Gsk 88.34 Bn 83.66 Bn - 4.68 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 22.05 Bn
Dec 28, 2025 20.10 Bn
Sep 28, 2025 18.56 Bn
Jun 29, 2025 18.88 Bn
Mar 30, 2025 38.78 Bn
Dec 29, 2024 24.52 Bn
Sep 29, 2024 20.30 Bn
Jun 30, 2024 25.48 Bn
Mar 31, 2024 26.22 Bn
Dec 31, 2023 22.93 Bn
Oct 1, 2023 23.51 Bn
Jul 2, 2023 28.51 Bn
Apr 2, 2023 24.61 Bn
Jan 1, 2023 22.28 Bn
Oct 2, 2022 34.08 Bn
Jul 3, 2022 32.57 Bn
Apr 3, 2022 30.39 Bn
Jan 2, 2022 31.61 Bn
Oct 3, 2021 31.00 Bn
Jul 4, 2021 25.31 Bn
Apr 4, 2021 24.62 Bn
Jan 3, 2021 25.19 Bn
Sep 27, 2020 30.78 Bn
Jun 28, 2020 19.14 Bn
Mar 29, 2020 18.02 Bn
Dec 29, 2019 19.29 Bn
Sep 29, 2019 17.95 Bn
Jun 30, 2019 15.28 Bn
Mar 31, 2019 15.34 Bn
Dec 30, 2018 19.69 Bn
Sep 30, 2018 19.36 Bn
Jul 1, 2018 18.14 Bn
Apr 1, 2018 15.20 Bn
Dec 31, 2017 18.30 Bn
Oct 1, 2017 16.23 Bn
Jul 2, 2017 12.85 Bn
Apr 2, 2017 39.34 Bn
Jan 1, 2017 41.91 Bn
Oct 2, 2016 40.43 Bn
Jul 3, 2016 42.58 Bn
Apr 3, 2016 39.86 Bn
Jan 3, 2016 38.38 Bn
Sep 27, 2015 37.31 Bn
Jun 28, 2015 33.95 Bn
Mar 29, 2015 31.32 Bn
Dec 28, 2014 33.09 Bn
Sep 28, 2014 33.01 Bn
Jun 29, 2014 31.62 Bn
Mar 30, 2014 29.39 Bn
Dec 29, 2013 29.21 Bn
Sep 29, 2013 25.23 Bn
Jun 30, 2013 25.13 Bn
Mar 31, 2013 21.67 Bn
Dec 30, 2012 21.09 Bn
Sep 30, 2012 19.77 Bn
Jul 1, 2012 16.92 Bn
Apr 1, 2012 33.85 Bn
Jan 1, 2012 32.26 Bn
Oct 2, 2011 30.93 Bn
Jul 3, 2011 29.68 Bn
Apr 3, 2011 26.87 Bn
Jan 2, 2011 27.66 Bn
Oct 3, 2010 22.13 Bn
Jul 4, 2010 18.90 Bn
Apr 4, 2010 18.01 Bn
Jan 3, 2010 19.43 Bn
Sep 27, 2009 14.34 Bn
Jun 28, 2009 14.72 Bn
Mar 29, 2009 12.59 Bn